Evogene is a leading computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. Incorporating a deep understanding of biology and leveraging Big Data and Artificial Intelligence, Evogene established its unique technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. Evogene holds a number of subsidiaries utilizing the CPB platform to develop human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production.
| Revenue (Most Recent Fiscal Year) | $8.51M |
| Net Income (Most Recent Fiscal Year) | $-16.49M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 0.88 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.48 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -254.09% |
| Net Margin (Trailing 12 Months) | -224.82% |
| Return on Equity (Trailing 12 Months) | -102.40% |
| Return on Assets (Trailing 12 Months) | -39.19% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.06 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.92 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 2.56 |
| Book Value per Share (Most Recent Fiscal Quarter) | $2.31 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.69 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 5.37M |
| Free Float | 4.97M |
| Market Capitalization | $5.96M |
| Average Volume (Last 20 Days) | 0.05M |
| Beta (Past 60 Months) | 1.55 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 7.40% |
| Percentage Held By Institutions (Latest 13F Reports) | 10.40% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |